During the past decade, Sarkis Clinical Trials conducted 66 clinical trials. In the 10-year time frame, 66 clinical trials started and 54 clinical trials were completed, i.e. on average, 81.8% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 27 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarkis Clinical Trials" #1 sponsor was "Shire" with 17 trials, followed by "Sunovion" with 10 trials sponsored, "Pfizer" with 9 trials sponsored, "Allergan" with 5 trials sponsored and "Janssen Research & Development, LLC" with 5 trials sponsored. Other sponsors include 55 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarkis Clinical Trials" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Paidion Research, Inc." with 2 trials as a collaborator, "Purdue Pharma LP" with 2 trials as a collaborator, "Janssen, LP" with 1 trials as a collaborator and "Otsuka America Pharmaceutical" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Sarkis Clinical Trials" are "ADHD" (11 trials), "Depressive Disorder, Major" (11 trials), "Major Depressive Disorder" (10 trials), "Attention Deficit Hyperactivity Disorder (ADHD)" (8 trials) and "Attention Deficit Hyperactivity Disorder" (5 trials). Many other conditions were trialed in "Sarkis Clinical Trials" in a lesser frequency.

Most popular intervention types in "Sarkis Clinical Trials" are "Drug" (94 trials), "Other" (10 trials), "Biological" (2 trials), "Diagnostic Test" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (49 trials), "Etrasimod" (3 trials), "Rapastinel" (3 trials), "eszopiclone" (3 trials) and "placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Sarkis Clinical Trials" are 103 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Sarkis Clinical Trials". undefined are not yet recruiting, 11 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 76 completed trials in Sarkis Clinical Trials, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Sarkis Clinical Trials, 1 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 70 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 6 trials that are defined as “Not Applicable".